HomeArticlesClinicalEffect of aging on stem cells
ClinicalLongevityAging

Effect of aging on stem cells

Source:NIH
Published:2017

How Aging Impacts Stem Cells

Introduction to Stem Cell Aging

At Forever Labs, we are dedicated to helping individuals preserve their youthful vitality by banking their mesenchymal stem cells (MSCs) for future regenerative therapies. Our autologous stem cell banking service at foreverlabs.com stores your young, potent bone marrow-derived MSCs, ensuring they are available for personalized treatments as you age. A comprehensive review published in Ageing Research Reviews titled “Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells” explores how aging affects MSC function, offering critical insights into why banking younger cells is a proactive step for future health. Let’s delve into this research and its implications for regenerative medicine with Forever Labs.

The Study: Aging’s Effects on MSC Function

Published in February 2017 by researchers including Anastasia Efimenko and colleagues, this review synthesizes data on how aging alters the regenerative properties of MSCs from bone marrow, muscle, and adipose tissue. MSCs are prized for their ability to differentiate into various cell types, modulate inflammation, and secrete regenerative factors, making them key players in therapies for aging-related conditions like osteoarthritis, frailty, and tissue repair. However, aging impacts MSC quantity, quality, and functionality, which can limit their therapeutic efficacy.

Key Mechanisms of MSC Aging

The review identifies several ways aging affects MSCs:

  • Reduced Proliferation and Quantity: Aging decreases MSC numbers in bone marrow and other tissues, with older individuals showing lower cell yields. Proliferation rates also decline, reducing the pool of viable cells for therapy.

  • Impaired Differentiation: Aged MSCs exhibit reduced capacity to differentiate into bone, cartilage, or fat cells, limiting their regenerative potential for tissue repair.

  • Altered Secretome: The bioactive molecules MSCs secrete, such as growth factors and cytokines, change with age. Older MSCs produce fewer pro-regenerative factors (e.g., VEGF) and more pro-inflammatory molecules, hindering tissue repair.

  • Increased Senescence: Aging promotes MSC senescence, where cells enter a state of arrested growth, accumulating DNA damage and reducing functionality.

  • Oxidative Stress and Microenvironment Changes: Age-related increases in oxidative stress and changes in the tissue microenvironment (e.g., bone marrow niche) impair MSC survival and performance.

These changes were consistent across bone marrow-, muscle-, and adipose-derived MSCs, though bone marrow MSCs showed particularly pronounced declines in regenerative capacity with age.

Experimental Evidence

The review cites studies showing that MSCs from older donors have reduced therapeutic efficacy in animal models. For example, in bone regeneration models, younger MSCs promoted faster healing and better bone formation than older MSCs. Similarly, in cardiac repair models, aged MSCs showed diminished ability to reduce inflammation or stimulate angiogenesis compared to younger cells. In vitro experiments further confirmed that aged MSCs have lower colony-forming efficiency and higher levels of senescence markers like p16 and p21. The review also notes that aging affects the MSC secretome, with older cells producing fewer extracellular vesicles (e.g., exosomes) critical for tissue repair.

Clinical Implications

The findings underscore a critical challenge for regenerative medicine: MSCs from older patients may be less effective for autologous therapies due to age-related declines. The authors suggest that banking MSCs at a younger age could preserve their regenerative potential, enabling more effective treatments later in life. This aligns with emerging clinical strategies to use younger, autologous cells for conditions like osteoarthritis, wound healing, and cardiovascular repair.

Why This Matters for Forever Labs

At Forever Labs, our mission is to bank your bone marrow-derived MSCs when they are at their peak potency—ideally in your 20s or 30s—through a minimally invasive, FDA-compliant procedure at foreverlabs.com. The Ageing Research Reviews study highlights why this is critical: younger MSCs have superior proliferation, differentiation, and regenerative capacities compared to aged cells. By preserving your MSCs now, you ensure access to high-quality cells for future therapies targeting age-related conditions. For example, your banked cells could be used to generate exosomes for tendon repair or direct injections for joint health, bypassing the limitations of aged MSCs. Autologous therapies, derived from your own cells, avoid immune rejection risks and align with the study’s call for optimized regenerative strategies.

The Broader Impact: Stem Cells and Healthy Aging

Aging’s impact on MSCs poses a significant hurdle for regenerative medicine, as older cells are less effective for treating conditions like frailty, osteoporosis, or chronic wounds. The review’s findings emphasize the value of proactive MSC banking to capture cells before age-related decline sets in. At Forever Labs, our cryogenic storage technology ensures your MSCs remain viable for decades, positioning you to benefit from emerging therapies that leverage younger cells’ superior regenerative properties. As research advances, with clinical trials exploring MSC applications for anti-aging, banking younger cells could be a game-changer for personalized medicine.

Take Charge of Your Regenerative Future

The Ageing Research Reviews study reveals that aging reduces MSC quantity and quality, limiting their therapeutic potential. At Forever Labs, we’re here to help you stay ahead of this decline by banking your MSCs at their prime. Visit foreverlabs.com to learn how stem cell banking can secure your regenerative potential for tomorrow’s breakthroughs.

Age smarter with Forever Labs.

Access Original Research

View the complete study and detailed methodology from the original source.

Read Full Study →

Related Articles

Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial

OBJECTIVE To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured by MRI. METHODS We conducted a multicenter, phase II, randomized trial including patients with secondary progressive or relapsing-remitting MS, with a documented increase in the last year on the Expanded Disability Status Scale, in spite of conventional therapy, and presence of one or more gadolinium-enhancing (Gd+) areas. Patients were randomized to receive intense immunosuppression (mobilization with cyclophosphamide and filgrastim, conditioning with carmustine, cytosine-arabinoside, etoposide, melphalan, and anti-thymocyte globulin) followed by AHSCT or MTX 20 mg every month for 6 months. The primary endpoint was the cumulative number of new T2 lesions in the 4 years following randomization. Secondary endpoints were the cumulative number of Gd+ lesions, relapse rate, and disability progression. Safety and tolerability were also assessed. Twenty-one patients were randomized and 17 had postbaseline evaluable MRI scans. RESULTS AHSCT reduced by 79% the number of new T2 lesions as compared to MTX (rate ratio 0.21, p = 0.00016). It also reduced Gd+ lesions as well as the annualized relapse rate. No difference was found in the progression of disability. CONCLUSION Intense immunosuppression followed by AHSCT is significantly superior to MTX in reducing MRI activity in severe cases of MS. These results strongly support further phase III studies with primary clinical endpoints.

Neurology2015
Read More

Intravenous transplantation of bone marrow-derived mononuclear cells prevents memory impairment in transgenic mouse models of Alzheimer's disease

Intravenous transplantation of bone marrow-derived mononuclear cells (BMMCs) successfully improved cognitive function and prevented neurodegeneration in two different Alzheimer's disease mouse models.

PubMed2015
Read More

Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research

Current evidence points toward stem cell therapy as an effective treatment for human patients with DFU

BMC2018
Read More